$3.76—
NASDAQ
$3.76—
Chiasma, Inc. is a biotechnology company focused on developing oral therapeutics for patients with rare diseases, particularly acromegaly. Its lead product, Mycapssa, is a novel treatment that offers a non-injectable option for patients, setting it apart in a market dominated by injectable therapies.
Chiasma generates revenue primarily through the sale of Mycapssa, which is marketed as a convenient oral treatment for acromegaly. The company benefits from a high gross margin of 94.5%, indicating strong pricing power in a niche market with limited competition. Its competitive advantage lies in the unique formulation of Mycapssa, which addresses a significant unmet need for patients seeking alternatives to injectable therapies.
Regulatory approvals for new indications or formulations of Mycapssa
Sales growth of Mycapssa in the U.S. and potential international markets
Partnerships or licensing deals to expand market reach
Clinical trial results for pipeline products
Regulatory changes impacting drug approval processes
Technological advancements in drug delivery systems that could render Mycapssa less competitive
Emergence of new oral therapies for acromegaly from competitors
Potential for established injectable therapies to improve their market positioning
High cash burn rate leading to potential liquidity issues if revenue does not increase
Dependence on a single product for revenue generation
low - Chiasma operates in a specialized segment of the healthcare market, which is less sensitive to economic cycles compared to broader consumer spending.
Interest rates have minimal direct impact on Chiasma's business, as it does not carry debt. However, rising rates could affect overall market sentiment and valuations in the biotech sector.
minimal - Chiasma has no debt, reducing its exposure to credit market fluctuations.
growth - investors interested in high-risk, high-reward opportunities in the biotech sector may find Chiasma appealing.
high - the stock is likely to exhibit high volatility due to its dependence on clinical trial outcomes and regulatory approvals.